US FDA approves Takeda, Protagonist's drug for rare blood cancer

By Kamal Choudhury and Mariam Sunny Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved a first-of-its-kind ...
JD Supra

FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List

On April 30, 2026, the U.S. Food and Drug Administration (FDA) announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List (“503B Bulks ...

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with ​metastatic pancreatic cancer who have received prior treatment or ‌cannot receive ...

New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst

The approval gives Bristol-Myers Squibb Company (NYSE:BMY) another opportunity to strengthen its position in multiple myeloma ...
MedCity News

First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic ...
GlobalData on MSN

Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’

Pasatru demonstrated strong efficacy in a Phase III trial, helping patients reduce lesions and flare-ups.